

17311(AP)



1601 2/12
RECEIVED

APR 19 2001

TECH CENTER 1600/2900

0500
#1
05-4-d
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dolly et al.

Serial No.: 09/648,692

Filed: August 25, 2000

For: ACTIVATABLE
RECOMBINANT NEUROTOXINS

Examiner: Not Assigned

Group Art Unit: Not Assigned

) I hereby certify that this correspondence is being deposited
) with the United States Postal Service with sufficient postage
) as First Class Mail in an envelope addressed to:
) Information Disclosure Statement-Non Fee
) Assistant Commissioner for Patents, Washington, D.C. 20231 on:
) Date of Deposit: 9/22/00
) Person making Deposit: BONNIE FERGUSON
) Signature of person making deposit: Bonnie Ferguson
) Date of Signature: 9/22/00

INFORMATION DISCLOSURE STATEMENT

Box: Information Disclosure Statement-Non Fee
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant herewith submits form PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Copies of references newly referenced in this Information Disclosure Statement are submitted herewith.

17311(AP)
Serial No. 09/648,692

2

PATENT

As this Information Disclosure Statement is being submitted prior to three months after the filing date of this Application, no fee or certification is thought to be required, pursuant to 37 CFR §1.97(b). If Applicant is in error in this regard, please use Deposit Account 01-0885 for payment of any fee that may be due.

Respectfully submitted,

Date:

9/20/00



Carlos A. Fisher
Reg. No. 36,510
ALLERGAN, INC.
T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4920
Fax: 714-246-4249

APR 19 2001

TECH CENTER 1600/2900 Sheet 1 of 1

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17311(AP)	SERIAL NO.: 09/648,692
APPLICANT: Dolly et al	TITLE: ACTIVATABLE RECOMBINANT NEUROTOXINS
FILING DATE: August 25, 2000	GROUP: Not Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,989,545	11/23/1999	Foster et al			
	AB	4,683,202	7/28/1987	Mullis			
	AC	4,800,159	1/24/1989	Mullis			
	AD	5,919,665	7/6/1999	Williams			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AH	WO 95/32738	12/7/1995	PCT			
	AI	WO 99/55359	11/4/1999	PCT			
	AJ	WO 96/33273	10/24/1996	PCT			
	AK	WO 98/07864	2/26/1998	PCT			
	AL	WO 99/17806	4/15/1999	PCT			
	AM	WO 98/08540	3/5/1998	PCT			

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	AT	Tonello et al, "Tetanus and Botulinum Neurotoxins a Novel Group of Zinc-Endopeptidases", Intracellular Protein Catabolism, Adv. Exp. Med. & Biol. 389, pgs. 251-260 (1996)
	AU	Coffield et al, "The Site and Mechanism of Action of Botulinum Neurotoxin in Therapy with Botulinum Toxin, pgs. 3-13 (1994)
	AV	Dolly et al, "Probing the process of transmitter release with botulinum and tetanus neurotoxins" Seminars in Neuroscience, 6 (3): pgs. 149-158 (1994)
	AW	Foran et al, "Botulinum Neurotoxin C1 Cleaves both Syntaxin and SNAP-25 in Intact and Permeabilized Chromaffin Cells: Correlation with Its Blockade of Catecholamine Release", Biochem. 35: pgs. 2630-2636 (1996)
	AX	Borodic et al, "Pharmacology and Histology of the Therapeutic Application of Botulinum Toxin Application of Botulinum Toxins", pgs. 119-157 (1994)
	AY	Li et al, "A Single Mutation in the Recombinant Light Chain of Tetanus Toxin Abolishes Its Proteolytic Activity and Removes the Toxicity Seen After Reconstitution with Native Heavy Chain", Biochemistry 33, No. 22: pgs. 7014-7020 (1994)
	AZ	Zhou et al, "Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstruction with the Heavy Chain", Biochemistry 34: pgs. 15175-15181 (1995)
	BA	Lacy et al, "Crystal structure of botulinum neurotoxin type A and implications for toxicity" Nature Struct. Biol. Oct; 5 (10): pgs. 898-902 (1998)
	BB	Kurazono et al, "Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A", J. Biol. Chem.: pgs. 14721-14729 (1992)
	BC	Smith et al, "Mutagenesis at a Specific Position in a DNA Sequence", J. Biol. Chem. 253: No. 18, September 25 issue, pgs. 6651-6560 (1978)
	BD	Li et al, "Expression and Characterisation of the Heavy Chain of Tetanus Toxin: Reconstitution of the Fully-Recombinant Dichain Protein in Active Form", J. Biochem. 125: pgs. 1200-1208 (1999)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.